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Cancer Therapy: Preclinical
A Novel Synergistic Combination of Cyclophosphamide and Gene
Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice
Mariana Malvicini,1 Miguel Rizzo,1 Laura Alaniz,1,3 Federico Piñero,1 Mariana García,1,3
Catalina Atorrasagasti,1 Jorge B. Aquino,1,3 Viviana Rozados,2 O. Graciela Scharovsky,2
Pablo Matar,2,3 and Guillermo Mazzolini1,3
Abstract Purpose: Interleukin-12 (IL-12) is an immunostimulatory cytokine with potent antitumor
effects in several animal models. However, serious toxicity has been associated with its
systemic application in humans. Gene transfer has emerged as a tool to specifically
express therapeutic genes into the tumor/peritumoral milieu, thus avoiding systemic
toxicity. The aim of this study was to analyze whether subtherapeutic doses of an ad-
enovirus encoding IL-12 (AdIL-12) might synergize with low immunopotentiating doses
of cyclophosphamide in the treatment of colorectal carcinoma.
Experimental Design: The antitumor effect of combining a single low dose of cyclo-
phosphamide with an intratumoral injection of AdIL-12 was evaluated in an in vivo
murine colorectal carcinoma model. The immune responses achieved with different
treatments were monitored, comparing the effect of combining both therapies with
individual treatments.
Results:The combined therapy induced a complete tumor regression in >50%ofmice in a
synergistic fashion, and it significantly prolonged their survival. This strategy was supe-
rior to each single treatment in reducing both peripheral and splenic CD4+CD25+Foxp3+
regulatory T cells, increasing the number of activated dendritic cells, and inducing IFN-
γ-secreting CD4-positive T lymphocytes. Importantly, the combined treatment generated
a powerful tumor-specific CTL response. Consistently, a significant reduction in IL-10
levels was found. Our data suggest that the combination of nontoxic doses of cyclophos-
phamide with AdIL-12 allows the generation of good antitumoral responses, thus avoid-
ing undesired side effects of both agents.
Conclusions: Our data strongly support the use of a combination of cyclophosphamide
and AdIL-12 as a novel therapeutic strategy against colorectal carcinoma. (Clin Cancer
Res 2009;15(23):7256–65)
Colorectal carcinoma is the second most common cause of
cancer mortality in western countries (1). Over the last two dec-
ades, much attention has been given to immunotherapy as a
promising therapeutic strategy for the treatment of certain hu-
man tumors, including metastatic colorectal carcinoma (2).
One of the most frustrating consequences of the interaction be-
tween the immune system and tumors is the ability of cancer
cells to escape the immune response through different mechan-
isms, such as tumor-induced impairment of antigen presenta-
tion, activation of negative costimulatory signals, production
of immunosuppressive factors, and expansion and/or recruit-
ment of regulatory cells that may contribute to the immuno-
suppressive network (3).
Systemic administration of cytokines efficiently generates po-
tent immune responses against a number of tumors (4). How-
ever, high doses of cytokines are needed to achieve significant
antitumor effects that, unfortunately, are associated with severe
toxicity (5). Gene therapy has emerged as a strategy to allow
required levels of cytokine expression to tumoral/peritumoral
milieu (6). Interleukin 12 (IL-12) is one of the most potent
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antitumor cytokines. Multiple biological effects can account for
its efficacy, including the induction of a Th1 type response and
the activation of natural killer (NK) cells/natural killer
T cells (NKTs) and CTLs (7). IL-12 also has the ability to in-
crease expression of adhesion molecules on endothelial cells
(e.g., VCAM-1), thus facilitating tumor recruitment of activated
lymphocytes (8, 9). In addition, tumor angiogenesis is inhib-
ited by downstream mediators of the IL-12/IFN-γ pathway
(10, 11). The activity of IL-12 has been investigated in patients
with advanced solid and hematologic malignancies. With few
exceptions, however, the efficacy was low (12). The efficacy of
IL-12 gene transfer for advanced gastrointestinal tumors in an-
imal models has been consistently shown by different groups,
including ours (13–17). Intratumoral administration of AdIL-
12 in patients with advanced gastrointestinal carcinomas in a
phase I trial was a feasible and well-tolerated procedure that
exerted only mild antitumoral activity (18). Several factors
might account for the lack of clinical success of gene therapy
with IL-12 and other immunotherapies, but the immunosup-
pressive effect induced by cancer cells seems to be the most
important (19). It was also shown that IL-12 can synergize
its therapeutic effect when it is combined with other proce-
dures involving the simultaneous transfer of other genes or
non–gene-based strategies (20).
Cyclophosphamide is a widely known chemotherapeutic
agent (21) that has been used by several groups, including ours,
as an immunomodulatory agent against murine and human
cancers (22–25). We have previously shown that a single low-
dose cyclophosphamide can inhibit the metastasis of a B-cell
lymphoma (L-TACB) in a rat model, likely due to the induction
of potent immunomodulatory mechanisms that result in a sig-
nificant reduction in IL-10 levels (26). Moreover, cyclophos-
phamide was shown to induce a Th2/Th1 switch and to
increase the proliferative rate in spleen cells (27).
The objective of this study was to investigate the antitumor
activity of combined regimens using cyclophosphamide as an
immunomodulatory agent and gene transfer of IL-12 as an
immunostimulatory tool, aimed at increasing the effectiveness
of individual treatments in a murine colorectal carcinoma
model. We hereby show that a low dose of cyclophospha-
mide prior to AdIL-12 intratumoral injection results in a syn-
ergistic effect leading to eradication of >50% of colorectal
carcinoma. Consistently, a significant decrease in CD4+
CD25+Foxp3+ cells (regulatory T cells, or Tregs) and a signif-
icant increase in activated dendritic cells were observed under
combined treatment. In addition, the combined strategy in-
duced a significant increase in the number of IFN-γ-secreting
CD4-positive T lymphocytes. Thus, intratumor IL-12 adenovirus
gene transfer in animals pretreated with an immunomodulatory
dose of cyclophosphamide resulted in a significantly increased
antitumor effect. Furthermore, a potent enhancement in tu-
mor-specific CTL activity was also found and could account, at
least in part, for the improved effects of this therapeutic combi-
nation approach.
Materials and Methods
Animals and cell lines. Six- to eight-week-old male BALB/c mice
were purchased from Biofucal S.A. The animals were maintained at
our Animal Resources Facilities (School of Biomedical Sciences, Austral
University) in accordance with the experimental ethical committee and
the NIH guidelines on the ethical use of animals. The CT26 tumor cell
line, an undifferentiated murine colorectal carcinoma cell line estab-
lished from a N-nitroso-N-methylurethan–induced transplantable tu-
mor in BALB/c (H-2d) mice (kindly provided by Prof. Prieto,
University of Navarra, Spain) was herein used. Murine BNL methylcho-
lanthrene-transformed liver cell line and HEK 293 cells were obtained
from the American Type Culture Collection. YAC-1 cells (Moloney leu-
kemia virus–transformed lymphoma cell line derived from A/Sn mice)
were kindly provided by Dr. Mirta Giordano, Academia Nacional de
Medicina de Buenos Aires, Argentina. Cells were maintained in DMEM
supplemented with 10% heat-inactivated FCS, 2 mmol/L L-glutamine,
100 U/mL streptomycin, and 100 mg/mL penicillin and incubated at
37°C in a 5% CO2 humidified atmosphere.
Drugs. Cyclophosphamide (Filaxis) was dissolved in sterile water
at a concentration of 20 mg/mL and injected i.p. at the doses indicated.
Adenoviral vectors. Construction of a recombinant adenoviruses en-
coding for IL-12 (AdIL-12) and the lacZ reporter genes (Adβ-Gal) were
previously described (13). Recombinant adenoviruses were isolated
from a single plaque, expanded in 293 cells, and purified by double
cesium chloride ultracentrifugation (28). Purified viruses were exten-
sively dialyzed against 10 mmol/L Tris-1 mmol/L MgCl2 and stored
in aliquots at -80°C, and were carefully titrated by plaque assay. The
concentration of recombinant vectors was expressed as 50% tissue cul-
ture infectious doses (TCID50) per milliliter (29).
In vivo experiments. CT26 cells were injected at a dose of 5 × 105
cells s.c. into the right flank of BALB/c mice. Tumors were allowed to
reach approximately 85 mm3 in size before treatment was started. Ani-
mals were distributed in different groups and then treated: saline i.p.;
cyclophosphamide (50 mg/kg i.p., day 8); AdIL-12 (109 TCID50 Intra-
tumorally, day 9); cyclophosphamide (50 mg/kg i.p.) plus AdIL-12
(109 TCID50 i.t.); Adβ-Gal (109 TCID50 i.t.); and cyclophosphamide
(50 mg/kg i.p.) plus Adβ-Gal (109 TCID50 i.t.). Adenoviruses were di-
luted in saline (final volume 50 μL) and i.t. injected in a single site; no
leakage of material was observed after inoculations.
Tumor growth was assessed twice weekly by caliper measurement. To
study protective immunity, animals that were free of disease at 4 wk
after complete regression of primary tumors (8 wk after first tumor in-
oculation) were challenged with 5 × 105 CT26 cells on the left flank.
Translational Relevance
We hereby provide preclinical data regarding the
anticancer efficacy of a novel immunotherapy com-
bination between cyclophosphamide and adenoviral
gene transfer of IL-12 (AdIL-12) for the treatment of
colorectal carcinoma. Our approach successfully
combines chemotherapy and immunotherapy,
which in a synergistic manner was found to result
in decreased number of regulatory T cells, increased
IFN-γ–secreting CD4-positive T lymphocytes, en-
hanced activation of splenic dendritic cells, and a po-
tent specific CTL response using suboptimal doses
of both agents. As a result, the combined therapy
is shown to induce complete tumor eradication in
>50% of mice and to prolong their survival. Immu-
notherapy in different forms, such as cyclophospha-
mide plus AdIL-12, could be tested for overall clinical
benefit on top of conventional treatment regimens
that have evidenced improvement of survival. Thus,
the combination of cyclophosphamide-based che-
motherapy and gene therapy of IL-12 fulfills the
criteria to become a useful and strong tool for treat-
ment of colorectal carcinoma patients.
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Age-matched naive animals received the same amount of cells to serve
as controls. Mice were monitored for up to 3 months for measurement
of tumor size and survival. Tumor volume (mm3) was calculated by the
formula π/6 × larger diameter × (smaller diameter)2.
Sample preparation for Tregs and dendritic cells flow cytometry
analyses. BALB/c mice were injected with 5 × 105 CT26 cells s.c. into
the right flank (day 0) and tumors were allowed to reach 85 mm3 be-
fore treatment was started. The animals were distributed into different
groups and treated with saline, cyclophosphamide, AdIL-12, cyclophos-
phamide plus AdIL-12, Adβ-Gal, or cyclophosphamide plus Adβ-Gal
(n = 6/group). At day 15 (Tregs) or day 21 (dendritic cells), peripheral
blood was collected by cardiac puncture and anticoagulated with EDTA.
The mice were then sacrificed, spleens were excised, and single cell sus-
pensions were prepared. The pretreatment group was constituted by
splenocytes obtained from tumor-bearing mice of 8-d evolution.
Peripheral blood cells or splenocytes were stained with different conju-
gated antibodies as it follows: anti-Foxp3 (phycoeritrin; eBioscience), and
anti-CD4 (PECy5), anti-CD25 (FITC), anti-CD11c (FITC), anti-MHCII
(PE), and anti-CD80 (Allophycocyanin; BD Biosciences), and their re-
spective isotypes. Cell suspensions were then treated with RBC lysis
buffer (0.15 mol/L NH4Cl, 1 mmol/L KHCO3, 0.1 mmol/L Na2-EDTA)
and washed with PBS 1% bovine serum albumin. Then, cells were fixed
with 1% paraformaldehyde and subjected to flow cytometry (FACSCalibur,
BectonDickinson-BD). Data were analyzed using WinMDI software.
Detection of IFN-γ–producing T lymphocytes. IFN-γ–producing T
lymphocytes were detected and quantified using a mouse IFN-γ secre-
tion assay-detection kit from Miltenyi Biotec (Bergisch Gladbach).
BALB/c mice were inoculated with 5 × 105 CT26 cells s.c. (day 0),
and injected with saline or with cyclophosphamide 50 mg/kg i.p (day
8). Then, the mice were sacrificed and splenocytes were obtained. The
pretreatment group consisted of splenocytes from CT26-bearing mice at
8 d after tumor cell injection. Splenocytes (2 × 106 cells/mL) were cul-
tured in complete DMEM medium in 6-well plates for 24 h and then
infected with AdIL-12 or Adβ-Gal at multiplicity of inflection of 500
(>80% of efficacy; data not shown). Five days later, cells were harvested,
washed, and labeled for 5 min at 4°C with an IFN-γ–specific high--
affinity capture matrix (a bispecific antibody-antibody conjugate). Cells
were then transferred into warm medium to allow secretion of cyto-
kines for 45 min at 37°C. Cells were then washed and stained with
anti-IFN-γ-PE for 10 min at 4°C. For FACS analysis, aliquots of all
samples were further stained with anti-CD4-PECy5 and anti-CD8-Alexa
Fluor 488 (BD Biosciences). Then, cells were fixed with 1% paraformal-
dehyde and subjected to flow cytometry (FACSCalibur, BectonDickinson-
BD). Data were analyzed using WinMDI software.
Measurement of IFN-γ and IL-10. Splenocytes from saline or cyclo-
phosphamide-treated CT26 tumor–bearing mice were harvested on day
4 posttreatment and cultured at 2 × 106 cells/mL of complete RPMI me-
dium in 6-well culture plates for 24 h. Then, cells were transduced with
AdIL-12 or Adβ-Gal at a multiplicity of inflection of 500. After incuba-
tion for 48 h (IL-10) or 120 h (IFN-γ) at 37°C and 5% CO2, culture
supernatants were collected and stored at -20°C.
To measure the effect of cyclophosphamide on IL-10 production
in vivo, BALB/c mice were inoculated with 5 × 105 CT26 cells s.c into
the right flank (day 0), and then a single dose of cyclophosphamide
of 50 or 100 mg/kg i.p. was administered 8 d after tumor inoculation.
A saline group was included as control. Blood samples, taken from the
tail vein, were collected on days 0, 12, 15, and 26 and stored at -20°C.
IFN-γ and IL-10 were measured by a sandwich ELISA assay (OptEIA, BD
Biosciences Pharmingen). The assays were carried out according to the
instructions provided by the manufacturer. Standards and samples were
assayed in duplicates.
Cytotoxicity assay. Cytotoxicity assay was done according to stan-
dard protocols (30). Viable splenocytes (8 × 106) were stimulated
in vitro with mitomycin C–treated CT26 cells (8 × 105 cells/well in
24-well-plates). On day 5, cells were harvested and washed, adjusted
to 4 × 106/mL, and added to 96-well-plate (effector cells). To determine
specific CTL cytotoxicity and NK activity three types of target cells were
used (CT26, BNL, and YAC-1) at 4 × 105/mL. After incubation for 4 h at
37°C, plates were centrifuged and cell-free supernatants were obtained.
Cytotoxicity was evaluated with the LDH Cytotoxicity Detection Kit
(Roche Diagnostics) following the manufacturer's instructions.
Proliferation assay. To measure the proliferation of spleen lympho-
cytes under different experimental conditions in response to mitomycin
C–treated CT26 cells, [3H]thymidine incorporation assay was done. In
vitro stimulation was carried out for 5 d in 24-well plates, with each well
containing 8 × 106 splenocytes and 8 × 105 mitomycin C–treated CT26
cells. Each sample was assayed in triplicate.
Histology. Tumor samples from all experimental groups were ob-
tained 15 d after treatment and fixed in 10% phosphate-buffered for-
malin. Five-micrometer sections from paraffin-embedded tissues were
stained with H&E for histologic examination.
Statistical analysis. Mann-Whitney test or Student's t-test (InStat,
GraphPad Software) was used to statistically examine the differences
between groups. P <0.05 was considered statistically significant.
Results
Intratumoral injection of AdIL-12 or systemic injection of cyclo-
phosphamide induces minor therapeutic effects. The aim of our
first experiments was to find the lowest nontoxic doses of cyclo-
phosphamide and AdIL-12 that could have significant antitu-
moral effects when used in combined strategies. The activity
of cyclophosphamide on the immune system of tumor-bearing
host is highly dose-dependent. Thus, high doses of cyclophos-
phamide (in mice, 100-150 mg/kg) usually bring about an im-
pairment of the host defense mechanisms along with the
reduction of tumor mass, leading to severe immunosuppres-
sion. In contrast, cyclophosphamide at low doses (∼50 mg/
kg) leads to an enhancement of the immune response resulting
in the inhibition of the tumor growth (31). To this aim, CT26
cells were s.c. injected into syngeneic BALB/c mice (day 0). On
day 8, animals with tumors reaching 85 mm3 in size received a
single i.p. injection of cyclophosphamide: 50, 100, or 150 mg/
kg. High doses of cyclophosphamide (100 and 150 mg/kg) in-
duced a significant tumor volume reduction in comparison
with the saline group (90% and 96% at day 28, respectively;
P < 0.05) and complete tumor regression in 33% (3 of 9)
and 50% (2 of 4) of animals, respectively (0% tumor regression
was observed in saline group). On the other hand, a lower dose
of cyclophosphamide (50 mg/kg) induced a tumor volume re-
duction of 72% when compared with the saline group and in-
duced a complete tumor regression in 13% of mice (1 of
8 animals; Fig. 1A). We have previously shown in a rat B-cell
lymphoma that a single low dose of cyclophosphamide is able
to reduce IL-10 production by T cells and to inhibit metastases
(26). Accordingly, we measured IL-10 serum levels in CT26-
bearing mice after different doses of cyclophosphamide. As
shown in Fig. 1B, IL-10 levels in saline-treated (control)
CT26-bearing mice increased significantly on days 15 and 26
compared with healthy animals (day 0). Interestingly, treat-
ment with 50 mg/kg cyclophosphamide (low dose) led to a sig-
nificant decrease in serum IL-10, reaching the basal levels from
day 15 onward. In contrast, IL-10 levels in mice treated with
100 mg/kg cyclophosphamide (high dose) were similar to the
saline group on days 15 and 26.
We afterwards determined the dose of AdIL-12 to be used.
When tumors reached approximately 85 mm3 in size, different
doses of AdIL-12, ranging from 108 to 109 TCID50, were i.t.
administered. AdIL-12 at 108 TCID50 induced 55% of tumor
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volume reduction with respect to the saline group at day 25,
and complete tumor regression in 7% of mice (1 of 14). A more
important tumor volume reduction was observed when 109
TCID50 of AdIL-12 were used instead, with a complete tumor
regression in 2 of 14 animals (14%; Fig. 1C). No saline- or Adβ-
Gal–treated animals showed tumor regression.
In view of previous results, we decided to evaluate the com-
bination of the lowest dose of each treatment that displayed
similar antitumor activities (equipotent doses) to analyze the
in vivo antitumor interaction effects of the combination of both
treatments. Therefore, a dose of 50 mg/kg for cyclophospha-
mide and of 109 TCID50 for AdIL-12 were chosen.
A sequential combination of a single low-dose cyclophosphamide
and an i.t. injection of suboptimal doses of AdIL-12 displays syn-
ergistic antitumor effects against colorectal carcinoma. To ex-
amine the antitumor effects of the combined treatment, CT26
tumor–bearing mice were treated, on day 8 after tumor inocu-
lation, with a single low dose of 50 mg/kg cyclophosphamide i.
p., and they were injected i.t. 24 hours later with 109 TCID50 of
AdIL-12. Animals treated with each single agent, Adβ-Gal in
combination with cyclophosphamide, or saline were also in-
cluded as required controls. The antitumor effects obtained
with cyclophosphamide or AdIL-12 alone were similar to those
obtained in the dose-response experiments [versus saline group:
77% and 76% of reduction in tumor volume, and complete tu-
mor regression in 8% (1 of 12) and 18% (2 of 11), respective-
ly]. In striking contrast, the combination of these suboptimal
doses of cyclophosphamide and AdIL-12 consistently resulted
in a marked tumor volume reduction (96% with respect to sa-
line group, at day 24) and complete tumor regressions in 6 of
12 animals (50% versus 0% in saline group; P < 0.05). In ad-
dition, the combined treatment produced a significant reduc-
tion of tumor volume when compared with animals treated
with each single agent from day 18 on (day 28: cyclophospha-
mide plus AdIL-12, 304 ± 154 mm3; cyclophosphamide, 1,534 ±
489 mm3; AdIL-12, 1,720 ± 512 mm3; P < 0.05; Fig. 2A). Such
a potent result did not reflect transgene-unrelated effects caused
by adenovirus combination with cyclophosphamide because
similar doses of Adβ-Gal combined with cyclophosphamide
did not show any significant change in tumor growth beyond
a typical response achieved with cyclophosphamide alone. The
combined cyclophosphamide plus AdIL-12 strategy was well
tolerated with no signs of toxicity (data not shown). Survival
of mice receiving combined therapy was significantly increased
compared with mice receiving each single treatment or saline
(P < 0.001) (Fig. 2B). Analysis of the in vivo interaction between
both treatments was done by the fractional product method
(32). Table 1 summarizes the relative tumor volume of different
groups on three different time points. On day 6 after treatment, in
the combination group there was a 1.1-fold improvement in
the treatment antitumor efficacy when compared with the ex-
pected additive effect. Moreover, on days 13 and 22, the com-
bination of cyclophosphamide and AdIL-12 showed a 1.3-fold
increase in the inhibition of tumor growth over an additive ef-
fect (expected fractional tumor volume). These results allow us
to conclude that the cyclophosphamide (50 mg/kg)–AdIL-12
(109 TCID50) combined therapy has a synergistic effect on tumor-
growth inhibition.
Microscopic examination of tumor sections obtained 15 days
after treatment showed gross areas of necrosis only in tumors
treated with AdIL-12 plus cyclophosphamide (Fig. 2C). In
Fig. 1. A, dose-response study for cyclophosphamide. BALB/c mice were
s.c. injected with 5 × 105 CT26 cells into the right flank (day 0) and tumors
were allowed to reach 85 mm3 before treatment. Animals were treated
with: saline (control); cyclophosphamide i.p 50, 100, or 150 mg/kg/body
weight. Tumor growth was assessed twice a week by caliper measurement.
Data are expressed as mean tumor volume (bars, SE). CR (%),
percentage of animals with complete tumor regressions. *, P < 0.05,
cyclophosphamide 100 and 150 mg/kg versus saline. B, measurement of
serum IL-10 concentration in CT26 tumor–bearing mice treated with saline
or a single dose of cyclophosphamide 50 or 100 mg/kg i.p 8 d after
tumor inoculation. Data are expressed as mean serum concentration
(bars, SE). *, P < 0.05, cyclophosphamide 50 mg/kg versus saline. C, dose
response study for AdIL-12. BALB/c mice were s.c. injected with 5 × 105
CT26 cells into the right flank (day 0) and tumors were allowed to reach
85 mm3 before treatment was started. Animals were treated with: saline
(control), Adβ-Gal, AdIL-12 108 TCID50, or AdIL-12 109 TCID50 i.t. Tumor
growth was assessed twice a week by caliper measurement. Data are
expressed as mean tumor volume (bars, SE). Student's t test was used to
compare differences among groups.
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addition, tumors treatedwith the combination showed amarked
infiltration of inflammatory mononuclear cells (not shown).
Long-term antitumor immunity induced by combined treat-
ment. To determine whether combined treatment can induce
lasting immunologic memory, we rechallenged animals that
were free of tumors with a new s.c. inoculation of CT26 tumor
cells (in the contralateral flank) at 4 weeks after complete re-
gression of primary tumors. A rejection in 6 of 6 animals
(100%) was observed after the second challenge with CT26
cells (Fig. 2D). In contrast, 5 of 5 mice treated with saline de-
veloped tumors and by day 28 they had died. These data indi-
cate that therapy using a combination of cyclophosphamide
and AdIL-12 can induce long-term protection against colorectal
carcinoma recurrence.
Assessment of CD4+ CD25+Foxp3+ regulatory T cells in periph-
eral blood and spleen. The prevalence of CD4-positive T cells
coexpressing CD25 and Foxp3 (Tregs) was determined in pe-
ripheral blood and spleen using triple-staining flow cytometry.
The ratio CD4+CD25+Foxp3+/CD4+ in the peripheral blood
and spleen of healthy mice was found to be 5.5% and 1.3%, re-
spectively. During colorectal carcinoma progression, this ratio
was significantly increased, reaching about 8.7% and 5.3%, re-
spectively (pretreatment groups; P < 0.05; Fig. 3A and B). When
the proportion of CD4+CD25+Foxp3+ cells was analyzed at day
7 of treatment (15 days after tumor inoculation), the saline
group showed a further increase in Tregs (14.1% and 18.4%
in peripheral blood and spleen, respectively) when compared
with pretreatment groups (P < 0.01). The administration of cy-
clophosphamide as single therapy induced a significant decrease
in the percentage of Tregs in comparison with saline group (pe-
ripheral blood, 6.1%; spleen, 6.7%; P < 0.05), and similar results
were found after AdIL-12 treatment in spleen (8.8%; P < 0.05).
The combined strategy of cyclophosphamide and AdIL-12 in-
duced a decrease in the percentage of Tregs in both peripheral
Fig. 2. A, antitumor activity of cyclophosphamide, AdIL-12, and their combination in CT26 tumor model. BALB/c mice were s.c. injected with 5 × 105 CT26
cells into the right flank (day 0) and tumors were allowed to reach 85 mm3 before treatment was started. Animals were distributed into different groups:
saline, cyclophosphamide (50 mg/kg i.p., day 8), AdIL-12 (109 TCID50 i.t., day 9), cyclophosphamide (50 mg/kg i.p.) plus AdIL-12 (109 TCID50 i.t.),
Adβ-Gal (109 TCID50 i.t.), and cyclophosphamide (50 mg/kg i.p.) plus Adβ-Gal (109 TCID50 i.t.). Data are expressed as mean tumor volume (bars, SE).
**, P < 0.01, cyclophosphamide and AdIL-12 versus AdIL-12 plus cyclophosphamide, from day 18 onward. Student's t test was used to compare tumor
sizes among different groups. B, survival of animals after treatment with each single treatment and the combination (Kaplan-Meier, log rank test, P < 0.001).
C, histologic examination of tumor samples from mice treated with saline and combination of AdIL-12 plus cyclophosphamide. Representative
H&E-stained sections. D, long-term protection against CT26 cells rechallenge at distant sites. CT26 cells (5 × 105 cells) were s.c. inoculated on the left flank
of animals that had been cured after treatment of established tumor with the combination of cyclophosphamide and AdIL-12 (4 wk after complete
regression). Age- and sex-matched naive animals inoculated with CT26 cells were also included as control. Deaths of animals were documented, and results
were expressed as the percentage of animal survival (Kaplan-Meier, log rank test, P < 0.01).
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blood and spleen similar to that of cyclophosphamide-alone ap-
plication (7.9% and 6.0%, respectively; P < 0.05 versus saline).
Effect of the combination of cyclophosphamide and AdIL-12 on
dendritic cells. Recent experimental evidence suggests that
Tregs might modulate the maturation and/or functional sta-
tus of dendritic cells (33). Considering our results regarding
Tregs, we decided to investigate the effects of the AdIL-12
plus cyclophosphamide combination on possible changes in
the proportion and maturation status of dendritic cells in the
spleen of mice with colorectal carcinoma. Fourteen days after
treatment, a significantly higher proportion of spleen CD11c+
MHC-II+CD80+ cells was found in cyclophosphamide-treated
animals (3.5%) when compared with the saline group
(1.8%; P < 0.05). Interestingly, and although the percentage
of dendritic cells in the group treated with AdIL-12 alone
(1.8%) was similar with that in the saline group, the com-
bination of AdIL-12 with cyclophosphamide induced a fur-
ther increase in the percentage of mature dendritic cells
(4.8%; Fig. 3C).
Cyclophosphamide pretreatment increased IFN-γ–producing T
lymphocytes after gene transfer of IL-12. The AdIL-12 plus cy-
clophosphamide combination is able to eradicate colorectal
carcinoma tumors through synergistic induction of efficient
immune responses. To confirm this possibility, we analyzed
the proportion of IFN-γ–secreting T lymphocytes in the
spleen of CT26 tumor–bearing mice. In this experiment, the
specific production of IFN-γ by CD4-positive or CD8-positive
splenic T lymphocytes of cyclophosphamide-treated CT26 tu-
mor–bearing mice was quantified after in vitro transduction
with AdIL-12. Administration of cyclophosphamide alone in-
creased the number of IFN-γ–secreting CD4-positive T lym-
phocytes (2.4%) as compared with the saline group (1.6%;
P < 0.05; Fig. 4A and B). A similar result was observed in
non–cyclophosphamide-treated mice after in vitro transduc-
tion with AdIL-12 (2.8%; P < 0.05). However, the combined
treatment (cyclophosphamide in vivo plus AdIL-12 in vitro)
led to a ∼3-fold increment in the number of IFN-γ–secreting
CD4-positive T lymphocytes (6.3%; P < 0.01, versus cyclo-
phosphamide and AdIL-12). No changes in the percentage
of IFN-γ–secreting CD8-positive T lymphocytes were detected
in between treatments (data not shown).
Effects of combined treatment on cytokine production profile.
As expected, the observed changes in the number of IFN-γ–
secreting CD4-positive T lymphocytes were found to correlate
with the levels of IFN-γ in supernatants from cultured sple-
nocytes. Splenocytes from mice bearing colorectal carcinoma
tumors at the beginning of treatment (pretreatment group)
produced low levels of IFN-γ in vitro (18 ± 3 pg/mL). Each
single treatment (cyclophosphamide or AdIL-12) induced a
slight increase in IFN-γ levels (150 ± 50 pg/mL and 227 ±
99 pg/mL, respectively) as compared with the saline group
(33 ± 13 pg/mL; P < 0.01). When AdIL-12 was applied in
combination with cyclophosphamide, a ∼5-fold increase in
IFN-γ production was found when compared with each sin-
gle therapy (1,332 ± 173 pg/mL; P < 0.01; Fig. 4C). In addi-
tion, cyclophosphamide alone or combined with AdIL-12
significantly reduced IL-10 production. As shown in Fig.
4D, IL-10 concentration increased with tumor growth from
day 8 (pretreatment, 102 ± 36 pg/mL) to day 12 (saline,
287 ± 84 pg/mL; P < 0.05). Cyclophosphamide alone or cy-
clophosphamide plus AdIL-12 induced a significantly de-
creased IL-10 production (59 ± 20 pg/mL and 53 ± 17 pg/
mL, respectively) in comparison with the saline group (P <
0.05). AdIL-12 alone did not significantly affect the concen-
tration of IL-10 (205 ± 52 pg/mL). This result suggests that
cyclophosphamide is responsible for the inhibition of IL-10
production and that AdIL-12 does not significantly influence
IL-10 production levels when applied in combination with
cyclophosphamide.
Low-dose cyclophosphamide and gene transfer of IL-12 synergize
to induce tumor-specific CTL activity. We next investigated
whether the antitumor effect induced by combined treatment
with cyclophosphamide and AdIL-12 was mediated by activa-
tion of NK and/or CTLs. As shown in Fig. 5A, treatment of
tumor-bearing mice with AdIL-12 or cyclophosphamide as
single therapy was found to elicit a mild cytotoxic activity
against CT26 cells. However, splenocytes harvested from mice
receiving the combined treatment displayed a significantly
higher lytic activity against CT26 after 5 days of in vitro re-
stimulation (P < 0.05). The specificity of cytotoxicity was
confirmed against BNL cells and the NK-sensitive target
YAC-1. Our data strongly suggest that cyclophosphamide
was able to enhance the specific CTL-promoting activity of
suboptimal gene transfer of IL-12 against CT26 colorectal car-
cinoma tumor cells. In addition, the AdIL-12 plus cyclophos-
phamide combined treatment was the only condition found
Table 1. Combined therapy with cyclophosphamide and AdIL-12
Fractional tumor volume* relative to untreated controls
Combination treatment
Day† Cy (50 mg/kg) AdIL-12 (109 TCID50) Expected‡ Observed R§
6 0.343 0.769 0.264 0.249 1.1
13 0.225 0.359 0.081 0.061 1.3
22 0.235 0.212 0.050 0.038 1.3
Abbreviation: Cy, cyclophosphamide.
*FTV, (experimental mean tumor volume)/(control mean tumor volume).
†Day after treatment onset.
‡(Cyclophosphamide mean FTV) × (AdIL-12 mean FTV).
§R = Expected FTV/Observed FTV. A ratio >1 indicates a synergistic effect, and a ratio <1 indicates a less than additive effect.
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to significantly increase the proliferation rate of splenocytes
(Fig. 5B).
Discussion
Multiple immunotherapy strategies for colorectal carcinoma
are currently under preclinical and clinical evaluation (34).
Some of them involve local administration of immunomodu-
latory molecules, such as cytokines, with the objective to induce
immunity against cancer cells (4, 5). Currently, one of the most
common approaches to transfer immunostimulatory molecules
inside tumors consists in the in vivo intratumoral/peritumoral
injection of vectors/cells expressing cytokines and/or costimula-
tory molecules genes (6, 35). Immunotherapy approaches usu-
ally have to face strong mechanisms of immune escape induced
by tumors (3). To increase the efficacy of passive or active im-
munotherapy strategies it seems reasonable to explore thera-
peutic interventions to intercourse tolerogenic processes, such
as those induced by Tregs in tumor-bearing hosts (36). In this
scenario, it has been shown that a low dose of cyclophospha-
mide not only decreases the number, but also inhibits the im-
munosuppression activity of the residual Tregs (37, 38).
Therefore, we decided to investigate the antitumor activity of
these two agents, IL-12 and cyclophosphamide, as a new ther-
apeutic combination for colorectal carcinoma. As expected, we
herein show that a low dose of cyclophosphamide and sub-
optimal doses of AdIL-12 cause a significant inhibition of a
protolerogenic response induced by colorectal carcinoma. Inter-
estingly, combined therapy was found to induce a significant
antitumoral response, as shown by higher i.t mononuclear cell
infiltrates, the induction of a potent specific CTL response and
of long-term immunity, and the increase in IFN-γ levels and in
the number of IFN-γ–secreting CD4-positive T lymphocytes.
The antitumoral immunologic response elicited by the com-
bined treatment was found to be highly efficient because
>50% of the mice showed tumor regression. In addition, ani-
mal survival was significantly increased when compared with
that of single-agent applications. Furthermore, our study shows
that the combination of a single low dose of cyclophosphamide
with AdIL-12 results from the synergistic potentiation of the
effect of both agents with regard to their antitumoral activities.
From all different dose combinations tested, a single ad-
ministration of 50 mg/kg cyclophosphamide 24 hours before
i.t. injection of 109 DICT50 of AdIL-12 was the optimal strat-
egy, both in dose levels and schedule. These results strongly
suggest that the reduction in numbers of CD4+CD25+FoxP3+
Treg cells and the increased activation of dendritic cells,
which might require the application of cyclophosphamide
prior to AdIL-12, is necessary to achieve the enhanced Th1-
type response observed.
Sequential systemic injection of cyclophosphamide followed
by intratumoral AdIL-12, in suboptimal doses, was able to in-
duce tumor regressions in ∼50% of the cases. This observation
is of particular importance for three reasons: (a) in our CT26
tumor model, AdIL-12 by itself failed to induce complete re-
gressions in >80% of the cases; (b) high doses of IL-12 can in-
duce severe toxicity; and (c) the synergistic effect achieved
suggest the possibility that a low dose of IL-12 could reach sig-
nificant antitumoral effects without toxicity.
Previous studies have shown that cyclophosphamide potenti-
ates the antitumor activities of a number of immunotherapeutic
Fig. 3. Percentage of CD4+CD25+Foxp3+/CD4+ cells (Tregs) in peripheral
blood.(A) or spleen (B). *, P < 0.05, pretreatment versus healthy;
**, P < 0.05, saline versus pretreatment; #, P < 0.05, cyclophosphamide,
AdIL-12, and AdIL-12 plus cyclophosphamide versus saline. C, percentage
of splenic CD11cMHC-II+CD80+ cells. *, P < 0.05, cyclophosphamide
and AdIL-12 plus cyclophosphamide versus saline; #, P < 0.05, AdIL-12 plus
cyclophosphamide versus cyclophosphamide. Mann-Whitney test was
used to compare differences among groups.
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strategies (25, 39). The immunomodulatory effects of cyclo-
phosphamide are not fully understood, but several mechanisms
have been proposed, including enhanced expansion of antigen-
specific T cells (40); stimulation of innate immune response, in
particular the activation of dendritic cells (41); induction of
type I IFN (42); Th2/Th1 shift in cytokines profile (27); and
elimination/inhibition of regulatory T cells (43). We herein
show that the AdIL-12 plus cyclophosphamide combined treat-
ment strongly reduced the number of CD4+CD25+Foxp3+ T
cells in both peripheral blood and spleen. The Tregs inhibition
observed was similar to that of cyclophosphamide-alone treat-
ment, indicating that cyclophosphamide is responsible for this
effect. Consistently, the reduction in the type-2 cytokine pro-
duction profile dominated by the presence of IL-10 was mainly
dependent on cyclophosphamide effects, causing a Th2/Th1
shift, characterized by significantly higher levels of IFN-γ. The
induction of a similar cytokine profile change was previously
observed by our group in a different tumor model (26, 27).
Taken together, these data suggest that cyclophosphamide pre-
treatment might modulate the immune system and perhaps the
tumor microenvironment, being able to potentiate the en-
hancement of the antitumoral activity mediated by IL-12 sub-
sequent application.
The response of tumor-bearing hosts to cyclophosphamide-
based therapy is heterogeneous, and no one mechanism alone
can entirely explain its immunomodulatory effects. It has been
recently shown that Tregs might induce tolerance status through
modulation of dendritic cell number and/or activity. It was
shown that Tregs render dendritic cells inefficient as antigen-
presenting cells and this effect was accompanied with increased
transforming growth factor-β and IL-10 secretion and reduced
expression of costimulatory molecules on dendritic cells (33).
We observed that cyclophosphamide alone as well as in com-
bination with AdIL-12 was able to increase the percentage of
activated dendritic cells. This effect might play a role in the ob-
served antitumor response induced by the combination. Hence,
we propose that Tregs inhibition induced by cyclophosphamide
may interfere with the negative feedback between Tregs and
dendritic cells likely potentiating the antitumor activity of
AdIL-12.
Fig. 4. A, percentage of splenic IFN-γ–secreting CD4-positive T lymphocytes. *, P < 0.05, cyclophosphamide and AdIL-12 versus saline; **, P < 0.01, AdIL-12
plus cyclophosphamide versus AdIL-12 and cyclophosphamide. B, representative density plots for A. C, IFN-γ quantification. *, P < 0.05, cyclophosphamide
and AdIL-12 versus saline; **, P < 0.01, AdIL-12 plus cyclophosphamide versus cyclophosphamide and AdIL-12. D, IL-10 quantification. *, P < 0.05,
saline versus pretreatment and healthy; #, P < 0.05, cyclophosphamide and AdIL-12 plus cyclophosphamide versus saline. Mann-Whitney test was used to
compare differences among groups.
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IL-12 has shown considerable antitumor activity in preclini-
cal models (7). However, the immunosuppressive mechanisms
frequently found in advanced tumors may likely limit the
efficacy of IL-12 and other kinds of immunotherapies (3). Thus,
we decided to investigate if immunomodulatory precondition-
ing of cyclophosphamide could enhance the IFN-γ production
induced by AdIL-12. Our results show that combined therapy
significantly increased IFN-γ secretion by CD4-positive T lym-
phocytes. The role of IFN-γ–producing CD4-positive T cells
would likely be the stimulation of tumor cell killing by macro-
phages (44) and of dendritic cells able to prime CTLs (45).
These results, together with the measurable effects on the mac-
roscopic tumor growth, were strengthened with histologic ex-
amination of excised tumors. The regression of CT26 tumors
treated with the combination was associated with extensive
areas of necrosis and inflammatory infiltrates. This phenome-
non was not observed using each agent alone nor was in seen
in nontreated tumors.
Altogether, our results suggest that the expansion of CD4+
CD25+Foxp3+ regulatory T cells and the increase in Th2 cyto-
kines production (particularly IL-10) during tumor progres-
sion might be responsible for the limited anticancer effect
of AdIL-12 as well as for other type of immunotherapy. In
our hands, depletion of CD4+CD25+Foxp3+ regulatory T cells
and a switch towards Th1 response can be achieved by a sin-
gle injection of low-dose cyclophosphamide. This effect has
the ability to potentiate the efficacy of gene therapy with
AdIL-12. This immunomodulatory approach seems to be an
attractive strategy to overcome the tolerance induced by colo-
rectal carcinoma and to tip the balance towards the genera-
tion of antitumor immunity. In this regard, we show herein
a remarkable increase in anti-CT26 CTL activity upon combined
treatment application, which is probably related to an ongoing
Th1 response induced by cyclophosphamide-mediated activa-
tion of CD4-positive T cells as well as by a reduction in CD4+
CD25+Foxp3+ cells. Nevertheless, other potential effects of the
combination could favor CTL generation such as the observed
necrosis of malignant tissue that could release tumor antigens
in a way suitable for presentation by dendritic cells (46).
These data support that a successful immunotherapy against
tumors requires the combination of two sequential manipula-
tions of the immune system: (a) immunomodulation, to make
the initial host immune response adequate against tumor cells,
and then (b) immunostimulation, to amplify anticancer im-
mune response into a strong T cell–mediated antitumor re-
sponse. The use of low-dose cyclophosphamide plus AdIL-12
in this study satisfies both requirements, possibly by cyclophos-
phamide-mediated elimination of immunosuppressive agents
and a further IL-12–mediated amplification of a Th1-type im-
mune response with the result of the generation of a potent
antitumor CTL activity.
Regardless of the specific mechanisms involved in the
observed antitumor effects, some of which have been herein
uncovered, we postulate the sequential administration of
cyclophosphamide followed by adenoviral gene transfer of IL-
12 as a potent tool for treatment of experimental colorectal car-
cinoma in mice. Furthermore, our results suggest this approach
as a potential tool for clinical treatment of colorectal carcinoma.
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Fig. 5. A, specific CTL activity. Splenocytes from different experimental
groups were stimulated in vitro with mitomycin-C–treated CT26 cells for
5 d. Specificity of CTL cytotoxicity and NK activity were evaluated using
BNL and YAC-1 cells, respectively. Cytotoxicity was evaluated with the LDH
Cytotoxicity Detection Kit. The percentage of specific cytotoxicity was
calculated according to the following formula: [(abs 492 nm experimental -
abs 492 nm background)/(abs 492 nmmaximum - abs 492 nm background)]
× 100. Data represent the mean of triplicate cultures. *, P < 0.05, AdIL-12
plus cyclophosphamide versus AdIL-12 and cyclophosphamide. B, cell
proliferation. Splenocytes from different experimental groups were
stimulated in vitro with mitomycin-C–treated CT26 cells for 5 d. Cell
proliferation was evaluated by 3H-thymidine incorporation assay at day 4.
*, P < 0.05, AdIL-12 plus cyclophosphamide versus AdIL-12 and
cyclophosphamide. Mann-Whitney test was used to compare differences
among groups.
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